Clovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving the way for a faster review if clinical trials work out.
China has carved itself a place as a major player in the pharma industry due to the number of clinical trials it is running, thanks to the reforms it has put in place.
Johnson & Johnson lawyers are gearing up to appeal a court ruling, which rewarded billions to 22 women in a case linking ovarian cancer and use of J&J's signature Baby Powder.
Breast cancer has been one area where checkpoint inhibitors have not yet gained traction – but that might be about to change following results announced by Tesaro at the American Society of
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl